(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/140174 A1

(51) International Patent Classification:
A61K 38/16 (2006.01) *A61P 13/12* (2006.01)

(21) International Application Number:
PCT/EP2021/050227

(22) International Filing Date:
08 January 2021 (08.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/959,698	10 January 2020 (10.01.2020)	US
63/037,832	11 June 2020 (11.06.2020)	US
63/089,386	08 October 2020 (08.10.2020)	US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).


(72) Inventors: **PARKER, Victoria**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **ROBERTSON, Darren**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **JERMUTUS, Lutz**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(74) Agent: **HUGHES, Rosemary**; AstraZeneca Intellectual Property, Milstein Building, Granta Park, Cambridge, Cambrigeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

WO 2021/140174 A1

(54) Title: GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES



Molecular Formula: $C_{167}H_{252}N_{42}O_{55}$
Molecular Weight: 3728.03618
HisSerGlnGlyThrPheThrSerAspLys[Glu.C(O)C16]SerGluTyrLeuAspSerGluArgAlaArgAspPheValAlaTrpValGluAlaGlyGly (SEQ ID NO:4)

FIG. 1

(57) Abstract: Provided herein are methods of improving glycemic control, reducing weight, decreasing urine albumin:creatinine ratio (UACR) and/or treating diabetic kidney disease (DKD) in a human patient with DKD and type 2 diabetes mellitus (T2DM) comprising administering a GLP- 1/glucagon agonist peptide such as Cotadutide. Provided herein are also methods of improving glycemic control, reducing weight, decreasing urine albumin:creatinine ratio (UACR) and/or treating chrnoic kidney disease (CKD) in a human patient comprising administering a GLP- 1/glucagon agonist peptide such as Cotadutide.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*